Bone as Regulator of Energy Balance and Male Fertility after SCI: A Pilot Study (Osteocalcin Protocol)

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is also accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- Male age 18-50 - diagnosis of motor complete spinal cord injury (SCI) - completed inpatient rehabilitation and living in the community - use a wheelchair as primary mobility mode -English and non-English speakers - For healthy volunteers: male age 18-50, able to walk independently, English and non-English speakers

Exclusion Criteria:

- presence of other neurological condition - use of chronic ventilator support - metabolic bone disease - thyroid disorder - current use of medications potentially affecting bone health (including bisphosphonates (etidronate or didronel, clodronate or bonefos, tiludronate or skelid, pamidronate, or aredia, alendronate or fosamax, ibandronate or boniva, risedronate or actonel, zoledronate or reclast) parathyroid hormone (forteo, teriparatide, abaloparatide), denosumab (prolia), testosterone, estrogen, anti-epileptics (phenytoin or dilantin, phenobarbital, valproic acid or depakene) lithium, glucocorticoid use for more than 3 months, and those who have received inhaled glucocorticoids in the past year) - study team will review additional exclusion criteria - for Healthy Volunteers: presence of neurological condition, metabolic bone disease, thyroid disorder, current use of medications that potentially affect bone healthy, osteoporosis, diabetes, infertility, or other medical conditions (study staff will review)

Conditions & Interventions

Conditions:
Brain & Nervous System
Keywords:
Spinal Cord Injury

More Information

Description: This study proposes a cross-sectional case-control pilot study. Spinal Cord Injury (SCI) is associated with altered bone metabolism, male infertility, and increased rates of insulin resistance. The researchers will perform testing for 30 men with SCI and 10 without SCI. Data will be used to power subsequent clinical trials. A Fairview letter of support has also been uploaded.
Contact(s): Leslie Morse - morsel@umn.edu
Principal Investigator: Leslie Morse
IRB
Number: STUDY00011054
System ID: 31736